The FDA has approved the use of Menactra for booster vaccination against meningococcal disease in patients aged 15–55 years.
Millions of infants and children aren't receiving recommended medical care aimed at detecting and preventing disease.
The CDC has reviewed evidence on the safety and efficacy of the herpes zoster vaccine in adults ages 50–59.
While initial vaccination rates are high, getting second doses and booster shots that are needed when children are 2 years old remains a challenge.
Pfizer announced that the FDA has granted Fast Track status for its investigational Clostridium difficile vaccine candidate (PF-06425090).
Needle-free injector for delivery of Afluria (trivalent, inactivated "split virus" influenza vaccine) in patients aged 18–64 years has been approved.
Review this clinical resource on 'Influenza Vaccine Comparisons' for fast information when you need it.
With this FREE certified-for-credit activity, review cases including "Vaccines in Childhood; Complex Regional Pain Syndrome".